Navigation Links
New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinson's Disease

BRUSSELS, June 15 /PRNewswire-FirstCall/ -- New data from a retrospective cohort study showed that up to three quarters of patients with Parkinson's disease (PD) developed gastrointestinal disorders (GID) that can have a substantial adverse effect on major PD-related clinical and health economic outcomes. These data were presented at the 14th International Congress of Parkinson's Disease and Movement Disorders in Buenos Aires, Argentina (June 13-17, 2010).

"The new retrospective cohort study suggested that the prevalence of gastrointestinal disorders among patients with Parkinson's disease was high, increased over time and had a significant impact on clinical and societal outcomes," said Dr. Florent Richy, Head of Epidemiology, UCB & Adjunct Professor of Epidemiology, University of Liege, Belgium. "Gastrointestinal disorders can impair the onset of symptom relief by Parkinson's disease drugs and these data help us to better understand the prevalence and consequences of such disorders amongst patients diagnosed with Parkinson's disease."

The study found that gastrointestinal disorders in PD patients were associated with significantly higher rates of neuropsychiatric and motor disorders, as well as increased emergency room admissions, number of concurrent drugs and non-PD healthcare costs.

About the Study

The new findings came from a two year matched retrospective cohort study performed on a U.S. database of patient records (Pharmetrics®)* which included demographic, diagnostic, procedural and prescription information. Patients with at least two prior diagnoses of Parkinson's disease and continuous prescriptions of levodopa or dopamine agonists between 1st September 2005 and 1st September 2006 were selected, and health outcomes and health utilization patterns were followed up over a two year period. Outcomes were defined on the basis of a literature review and included neuropsychiatric, motor, urogenital disturbances, healthcare utilization and related costs.

Four hundred and eighty five patients with Parkinson's disease and GID were matched with 485 patients with Parkinson's disease and without GID. In the data cut, GID incidence among patients with Parkinson's disease and no history of GID increased over time, stabilizing at 75% at 92 months.  In addition GID was associated with significantly higher rates of neuropsychiatric and motor disorders, including psychosexual dysfunction (RR=8, p=0.05), anxiety (RR=1.61, p<0.01), depression (RR=1.28, p=0.03), ataxia (RR=1.24, p=0.03), pain (RR=1.29, p<0.01), movement disorders (RR=1.39, p=0.02), urinary incontinence (RR=1.43, p=0.01) and risk of fall (RR=1.44, p=0.03). Emergency room admissions (ratio=1.42, p<0.01), number of concurrent drugs (ratio=1.06, p=0.04) and Parkinson's disease and non-Parkinson's disease healthcare costs (ratios=1.13 and 1.12, p<0.01 respectively) increased during the observation period in the GID patients.

* This study was performed using a licensed IMS Pharmetrics® datacut

Abstract: Gastrointestinal disorders in patients with Parkinson's Disease: A double-edged sword

Richy F1, Gunn A2, Makaroff L3, Gervasoni C4, Helmers S5

1UCB Pharma SA, Brussels, Belgium & University of Liege, Belgium; 2UCB Pharma SA, Brussels, Belgium; 3Business & Development, Life Sciences, Brussels Belgium; 4Keyrus Biopharma, Lasne, Belgium; 5Emory University School of Medicine, Atlanta, US

Poster Session I, June 14th 2010, 0900-1800

For further information

Eimear O Brien, Associate Director, Global CNS Communications

T +32 2 559 9271,

Andrea Levin / Public Relations Manager, CNS, UCB, Inc.

Office:  770.970.8352 / Mobile: 404.483.7329 / Email:

About UCB

UCB, Brussels, Belgium ( is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing more than 9 000 people in over 40 countries, UCB produced revenue of EUR 3.1 billion in 2009. UCB is listed on Euronext Brussels (symbol: UCB).

Forward looking statement

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.

Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Chiasma Reports Successful Oral Delivery Of A Peptide In Clinical Study
2. Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors
3. Two-Year Follow up Data of NuBac® IDE Feasibility Study Was Presented at SAS Meeting
4. Reaction Progress Kinetic Analysis to Study Organic Reactions: Free On-Demand Online Seminar
5. Study sheds light into the nature of embryonic stem cells
6. Study Evaluated Vyvanse® (lisdexamfetamine dimesylate) Capsules CII Efficacy and Safety in Adolescents with ADHD
7. Carolina Conceptions Announces New Egg Freezing Study to Help Women Preserve their Fertility
8. Volcano Announces Positive Clinical Experience With Its Second Generation OCT Catheter, Prepares for U.S. Regulatory Study
9. Oncolytics Biotech(R) Inc. Announces Phase I Colorectal Cancer Study
10. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-111 and Herceptin in Patients with Advanced Her2 Positive Breast Cancer
11. AXL1717 Clinical Data From Ongoing Phase I/II Study in Cancer Patients Will be Released in Connection With the ASCO Meeting in Chicago, June 2010
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading software as ... Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio and video ... trial team. , Using the CONSULT module, patients and physicians can schedule a face ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader ... “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, ... providing practical tips, tools, and strategies for clinical researchers. , “The landscape of ...
Breaking Biology Technology:
(Date:6/22/2016)... 2016   Acuant , the leading ... has partnered with RightCrowd ® to ... Management, Self-Service Kiosks and Continuous Workforce Assurance. ... functional enhancements to existing physical access control ... with an automated ID verification and authentication ...
(Date:6/15/2016)... ALBANY, New York , June 15, 2016 ... published a new market report titled "Gesture Recognition Market ... Trends and Forecast, 2016 - 2024". According to the ... at USD 11.60 billion in 2015 and is ... and reach USD 48.56 billion by 2024.  ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) ... million US Dollar project, for the , Supply ... Enrolment, and IT Infrastructure , to ... implementation of Identity Management Solutions. Numerous renowned international vendors participated ... was selected for the most compliant and innovative ...
Breaking Biology News(10 mins):